These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36157151)

  • 1. Nonalcoholic Fatty Liver Disease in Living Donor Liver Transplant Recipients: A Histology-Based Study.
    Choudhary NS; Saraf N; Dhampalwar S; Mishra S; Gautam D; Lipi L; Rastogi A; Bhangui P; Chaudhary RJ; Gupta A; Yadav K; Soin AS
    J Clin Exp Hepatol; 2022; 12(5):1328-1332. PubMed ID: 36157151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of living donor liver transplantation on long-term cardiometabolic and graft outcomes in cirrhosis due to nonalcoholic steatohepatitis.
    Karnam RS; Azhie A; Yang C; Rogalsky A; Chen S; Xu W; Patel K; Selzner N; Lilly L; Cattral M; Bhat M
    Clin Transplant; 2023 Sep; 37(9):e15008. PubMed ID: 37143204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis.
    Saeed N; Glass L; Sharma P; Shannon C; Sonnenday CJ; Tincopa MA
    Transplantation; 2019 Nov; 103(11):e345-e354. PubMed ID: 31415032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
    Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
    J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
    Galvin Z; Rajakumar R; Chen E; Adeyi O; Selzner M; Grant D; Sapisochin G; Greig P; Cattral M; McGilvray I; Ghanekar A; Selzner N; Lilly L; Patel K; Bhat M
    Liver Transpl; 2019 Jan; 25(1):56-67. PubMed ID: 30609189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant Non-alcoholic Fatty Liver Disease and Metabolic Syndrome After Living Donor Liver Transplantation in Indians.
    Choudhary NS; Dhampalwar S; Saraf N; Rastogi A; Bhangui P; Soin AS
    J Clin Exp Hepatol; 2024; 14(2):101281. PubMed ID: 38076440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living donor liver transplantation for non-alcoholic steatohepatitis: A single center experience.
    Tanaka T; Sugawara Y; Tamura S; Kaneko J; Takazawa Y; Aoki T; Hasegawa K; Sakamoto Y; Yamashiki N; Kokudo N
    Hepatol Res; 2014 Oct; 44(10):E3-E10. PubMed ID: 23834427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic steatohepatitis recurrence after liver transplant.
    Taneja S; Roy A
    Transl Gastroenterol Hepatol; 2020; 5():24. PubMed ID: 32258528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study.
    Alhinai A; Qayyum-Khan A; Zhang X; Samaha P; Metrakos P; Deschenes M; Wong P; Ghali P; Chen TY; Sebastiani G
    World J Hepatol; 2021 Dec; 13(12):2179-2191. PubMed ID: 35070018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 16. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 17. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology.
    Calleja JL; Rivera-Esteban J; Aller R; Hernández-Conde M; Abad J; Pericàs JM; Benito HG; Serra MA; Escudero A; Ampuero J; Lucena A; Sánchez Y; Arias-Loste MT; Iruzubieta P; Romero-Gómez M; Augustin S; Crespo J
    Liver Int; 2022 Aug; 42(8):1783-1792. PubMed ID: 35643936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
    Ester C; Cerban R; Iacob S; Pietrareanu C; Constantin G; Paslaru L; Ichim S; Lita M; Vadan R; Grancea C; Ruta S; Gheorghe C; Popescu I; Gheorghe L
    Chirurgia (Bucur); 2018; 113(4):534-541. PubMed ID: 30183584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.